Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Pelcitoclax - Ascentage Pharma

Next Previous
Drug Profile

Pelcitoclax - Ascentage Pharma

Alternative Names: APG 1252; APG 1252 12A; Palcitoclax

Latest Information Update: 02 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Ascentage Pharma
  • Class Amines; Aniline compounds; Antineoplastics; Chlorobenzenes; Fluorobenzenes; Phosphonic acids; Piperazines; Piperidines; Pyrroles; Small molecules; Sulfonamides; Sulfones
  • Mechanism of Action Bcl-X protein inhibitors; Proto-oncogene protein c-bcl-2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Small cell lung cancer
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer
  • Phase I/II Myelofibrosis; Non-Hodgkin's lymphoma; Small cell lung cancer
  • Preclinical T-cell lymphoma
  • No development reported Gastric cancer; Neuroendocrine tumours; Solid tumours

Most Recent Events

  • 15 Apr 2025 Ascentage Pharma Group terminates a phase I clinical trials in Neuroendocrine tumours (Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV) due to company strategy (NCT04893759)
  • 28 Dec 2024 No recent reports of development identified for phase-I development in Neuroendocrine-tumours(Late-stage disease, Metastatic disease, Second-line therapy or greater) in China (IV, Infusion)
  • 28 Sep 2024 No recent reports of development identified for preclinical development in Gastric-cancer in China

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top